Artal Group Sa Has Raised Position in Acceleron Pharma INC (XLRN) by $66.70 Million as Share Value Rose

Acceleron Pharma Inc. (NASDAQ:XLRN) LogoInvestors sentiment increased to 1.83 in 2019 Q1. Its up 0.72, from 1.11 in 2018Q4. It is positive, as 14 investors sold XLRN shares while 34 reduced holdings. 28 funds opened positions while 60 raised stakes. 46.76 million shares or 10.00% more from 42.51 million shares in 2018Q4 were reported. Kennedy Mgmt owns 116,670 shares or 0.13% of their US portfolio. Pnc Fincl Ser Inc has 0% invested in Acceleron Pharma Inc. (NASDAQ:XLRN). Alps Advisors Inc owns 0.04% invested in Acceleron Pharma Inc. (NASDAQ:XLRN) for 124,486 shares. Ameritas Invest Partners, Nebraska-based fund reported 3,593 shares. Geller Advsrs Llc accumulated 18,750 shares. Sectoral Asset Mgmt holds 269,396 shares or 1.51% of its portfolio. Riverhead Capital Mgmt Ltd Company invested 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Gsa Ptnrs Llp has invested 0.02% in Acceleron Pharma Inc. (NASDAQ:XLRN). Spark Investment Mngmt Ltd has invested 0.18% in Acceleron Pharma Inc. (NASDAQ:XLRN). Morgan Stanley reported 31,452 shares. Fincl Bank Of New York Mellon invested 0.01% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN). Neville Rodie Shaw Incorporated invested in 42,964 shares or 0.21% of the stock. 7,260 were reported by Nelson Van Denburg Campbell Wealth Mgmt Group. Blackrock has 4.80M shares for 0.01% of their portfolio. State Of New Jersey Common Pension Fund D accumulated 88,000 shares.

Since June 14, 2019, it had 1 buying transaction, and 0 selling transactions for $190,250 activity.

Artal Group Sa increased its stake in Acceleron Pharma Inc (XLRN) by 725% based on its latest 2019Q1 regulatory filing with the SEC. Artal Group Sa bought 1.45 million shares as the company’s stock rose 9.20% . The institutional investor held 1.65M shares of the biological products (no diagnostic substances) company at the end of 2019Q1, valued at $76.84 million, up from 200,000 at the end of the previous reported quarter. Artal Group Sa who had been investing in Acceleron Pharma Inc for a number of months, seems to be bullish on the $2.38B market cap company. The stock decreased 0.75% or $0.34 during the last trading session, reaching $45.02. About 119,085 shares traded. Acceleron Pharma Inc. (NASDAQ:XLRN) has risen 4.00% since August 15, 2018 and is uptrending. It has outperformed by 4.00% the S&P500.

Artal Group Sa, which manages about $2.45B US Long portfolio, decreased its stake in Audentes Therapeutics Inc by 200,000 shares to 400,000 shares, valued at $15.61 million in 2019Q1, according to the filing. It also reduced its holding in Bank Amer Corp (Call) (NYSE:BAC) by 2.50 million shares in the quarter, leaving it with 2.00 million shares, and cut its stake in Celgene Corp (Call) (NASDAQ:CELG).

More notable recent Acceleron Pharma Inc. (NASDAQ:XLRN) news were published by: Seekingalpha.com which released: “Acceleron completes enrollment in mid-stage study of sotatercept in PAH – Seeking Alpha” on June 26, 2019, also Seekingalpha.com with their article: “Acceleron prices stock offering – Seeking Alpha” published on January 16, 2019, Nasdaq.com published: “Acceleron Pharma (XLRN) Reports Q2 Loss, Tops Revenue Estimates – Nasdaq” on August 05, 2019. More interesting news about Acceleron Pharma Inc. (NASDAQ:XLRN) were released by: Streetinsider.com and their article: “Acceleron Pharma (XLRN) Misses Q2 EPS by 4c – StreetInsider.com” published on August 05, 2019 as well as Nasdaq.com‘s news article titled: “Celgene (CELG) Beats on Q2 Earnings, Raises Revenue Guidance – Nasdaq” with publication date: July 31, 2019.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Coverage

Among 5 analysts covering Acceleron Pharma (NASDAQ:XLRN), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Acceleron Pharma has $78 highest and $4500 lowest target. $60.40’s average target is 34.16% above currents $45.02 stock price. Acceleron Pharma had 10 analyst reports since February 26, 2019 according to SRatingsIntel. JP Morgan maintained the stock with “Overweight” rating in Tuesday, August 6 report. Goldman Sachs reinitiated it with “Neutral” rating and $5400 target in Wednesday, May 29 report. Barclays Capital downgraded the shares of XLRN in report on Friday, May 3 to “Equal-Weight” rating. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, February 26 report. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, March 5.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.